GSK 3050002

Drug Profile

GSK 3050002

Alternative Names: Anti-CCL20 monoclonal antibody; E 6071; GSK-3050002; KANAb-071

Latest Information Update: 23 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; KAN Research Institute
  • Developer GlaxoSmithKline; Morphotek
  • Class Monoclonal antibodies
  • Mechanism of Action CC chemokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psoriatic arthritis; Ulcerative colitis

Most Recent Events

  • 15 May 2018 Discontinued - Phase-I for Psoriatic arthritis in United Kingdom (IV) (Eisai pipeline, May 2018)
  • 15 May 2018 Discontinued - Phase-I for Ulcerative colitis in United Kingdom (IV) (Eisai pipeline, May 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis in United Kingdom (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top